StockMarketWire.com - Liquid biopsy company Angle said Tuesday that its cell separation technology system was subject to a further peer-reviewed publication in the British Journal of Cancer.

Work lead by Professor Nicola Aceto at the Cancer Metastasis Laboratory, University of Basel Basel had demonstrated that, the Parsortix system combined with a simple blood test could detect circulating tumour cells in human glioblastoma. The cells could then be analysed to provide molecular characterisation of the cancer.

'Basel has now shown that, as well as singular circulating tumour cells, clusters of circulating tumour cells will pass through the blood-brain barrier and can be harvested for analysis using the Parsortix system,' Angle said.

'The glioblastoma work is a further example of ground breaking research being undertaken by a Parsortix customer in addition to ANGLE's own efforts to commercialise the Parsortix system,' said ANGLE Founder and Chief Executive, Andrew Newland.

'University of Basel and their collaborators are working on the application of this approach for the treatment of glioblastoma patients and we look forward to reporting further developments in due course.'








At 10:08am: [LON:AGL] Angle PLC share price was +2p at 48.5p



Story provided by StockMarketWire.com